Increasing numbers of Phase I clinical trials are investigating the safety and efficacy of bispecific antibodies targeting PD-1 and LAG-3 across various cancers, including epithelial ovarian cancer (EOC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), cervical cancer, and cholangiocarcinoma 145. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.